Cereno Scientific’s Board of Directors and Executive Management enter into lock-up agreements
Cereno Scientific (Nasdaq First North: CRNO B) (the “Company”), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that its Board of Directors and Executive Management have signed lock-up agreements for their shares and/or other securities in the Company until topline results for the Phase II trial of the Company’s lead asset CS1 in the rare disease Pulmonary Arterial Hypertension (PAH) is presented in Q3, 2024.The members of the Board of Directors and Executive Management have entered into an agreement not to sell their shares